Frankfurt am Main, July 29, 2015 -- Moody's Investors Service, ("Moody's") has today affirmed the Probability of Default Rating and Corporate Family Rating of Hikma Pharmaceuticals PLC at Ba1-PD and Ba1 respectively. Concurrently Moody's has also affirmed the Ba1 rating on the USD500 million senior unsecured guaranteed notes issued by Hikma Pharmaceuticals PLC. The outlook on all ratings is stable.

Vollständigen Artikel bei Moodys lesen